6/23/2020 8:34:30 AM
Relmada Therapeutics Announces Notice Of Allowance For Patent In Canada Covering REL-1017 For Psychiatric Symptoms
5/27/2020 8:11:25 AM
Relmada Therapeutics Says Outcome Of End-of-Phase 2 Meeting With FDA For REL-1017; Says Can Proceed To Phase 3
3/9/2020 8:32:12 AM
Relmada Therapeutics Appoints Thomas Wessel As EVP, Head Of Research And Development
12/3/2019 11:09:31 PM
Relmada Therapeutics Announces Pricing Of Public Offering Of 3.33 Mln Shares At $30/Shr
12/3/2019 4:15:54 PM
Relmada Therapeutics Announces Proposed Public Offering Of Common Stock
10/15/2019 8:05:07 AM
Relmada Therapeutics Announces Top-Line Results From REL-1017 Phase 2 Study In Individuals With Resistant Depression
10/10/2019 8:35:23 AM
Relmada Therapeutics Announces Commencement Of Trading On NASDAQ
9/27/2019 1:06:01 PM
Relmada Therapeutics Announces 1-for-4 Reverse Stock Split